You are here: Industry Insights > Cabenuva

News List

Cabenuva HIV treatment approved for eight week dosing EuropeanPharmaceuticalReview
February 09, 2022
ViiV Healthcare has announced the US Food and Drug Administration’s (FDA) approval of Cabenuva (cabotegravir, rilpivirine) in the treatment of HIV.
US green light for long-acting HIV regimen Cabenuva pharmatimes
January 25, 2021
The US Food and Drug Administration (FDA) has approved ViiV Healthcare and Janssen’s long-acting regimen for HIV-1 infection Cabenuva (cabotegravir, rilpivirine).
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment expresspharma
January 22, 2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
ViiV Healthcare secures Canadian approval for HIV drug regimen CABENUVA pharmaceutical-business-review
March 25, 2020
ViiV Healthcare has secured approval for CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions) from Health Canada for the treatment of HIV-1 infection in adults.
Cabenuva (cabotegravir and rilpivirine) granted approval by Health Canada europeanpharmaceuticalreview
March 24, 2020
The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has been granted by Health Canada, in conjunction with use of Vocabria.
ViiV Healthcare, Janssen get Canadian approval for Cabenuva pharmaceutical-technology
March 24, 2020
ViiV Healthcare and Janssen Pharmaceutical have announced the Health Canada approval of Cabenuva as a once-monthly, long-acting therapy for adults with HIV-1 infection.
GSK's long-acting HIV injectable hits FDA snag fiercepharma
December 27, 2019
HIV patients looking for relief from the burden of daily pills will have to wait a little longer.GlaxoSmithKline’s ViiV Healthcare said that the FDA had rejected its long-acting HIV injection ...